DexCom logged higher third-quarter sales and authorized a share-buyback program of up to $1 billion.
The maker of glucose monitors posted a profit of $275.1 million, or 72 cents a share, compared with $283.8 million, or 70 cents a share, a year earlier.
Stripping out certain one-time items, adjusted per-share earnings were 73 cents, ahead of the 67 cents anticipated by analysts, according to FactSet.
Revenue rose 11%, to $1.34 billion. Analysts surveyed by FactSet forecast revenue of $1.33 billion. Sales were up 14% in the U.S. and 5% internationally.
DexCom now expects annual sales to be $5.2 billion to $5.25 billion, compared with its prior guidance of $5.18 to $5.25 billion.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments